Human Genome Sciences closes public offering of new issued shares

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the closing of its public offering of 17,825,000 newly issued shares of its common stock at a price to the public of $26.75 per share, which includes 2,325,000 shares sold upon exercise by the underwriters of their option to purchase additional shares. The net proceeds to the Company from the offering are approximately $456.3 million, after deducting the underwriting discount and estimated offering expenses.

Goldman, Sachs & Co. and Citigroup Global Markets Inc. acted as joint book-running managers for the offering, and J.P. Morgan Securities Inc., Morgan Stanley & Co. Incorporated, and UBS Securities LLC acted as co-managers for the offering.

The shares were issued pursuant to an effective shelf registration statement. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Human Genome Sciences, Inc., nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When available, a copy of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from Goldman, Sachs & Co., at 85 Broad Street, New York, New York 10004, Attention: Prospectus Department, Toll-Free 1-866-471-2526, or by email at [email protected] and Citigroup Global Markets Inc. at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, Attention: Prospectus Department, Toll-Free 1-800-831-9146.